News
WCLC: Daiichi Sankyo HER3 ADC readout sets up filings
A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the d
